These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6894966)

  • 1. Effects of vitamin D metabolites and analogues on renal function.
    Naik RB; Cundy T; Robinson BH; Russell RG; Kanis JA
    Nephron; 1981; 28(1):17-25. PubMed ID: 6894966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Requirements of vitamin D metabolites in patients with renal disease.
    Massry SG
    Am J Clin Nutr; 1980 Jul; 33(7):1530-5. PubMed ID: 6893103
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum concentrations of metabolites of vitamin D in patients with chronic renal failure (CRF). Consequences for the treatment with 1-alpha-hydroxy-derivatives.
    Juttmann JR; Buurman CJ; De Kam E; Visser TJ; Birkenhäger JC
    Clin Endocrinol (Oxf); 1981 Mar; 14(3):225-36. PubMed ID: 6973423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium and parathyroid disorders in children. Chronic renal failure and treatment with calcitriol.
    Chan JC; DeLuca HR
    JAMA; 1979 Mar; 241(12):1242-4. PubMed ID: 762789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of vitamin D metabolites on indicators of protein, phosphorus and calcium metabolism in children with chronic renal failure].
    Denisova SN; Kutafina EK; Sergeeva TV; Savina MI; Kon' IIa; Shilina NM; Chizhevskaia OL; Shilov AV
    Vopr Pitan; 1999; 68(5-6):35-40. PubMed ID: 10641280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin-D analogues and renal function.
    Christiansen C; Christensen MS; Hartnack B; Melsen F; Transbøl I; Rødbro P
    Lancet; 1979 Jan; 1(8106):50-1. PubMed ID: 83502
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of long-term therapy with calcitriol in patients with moderate renal failure.
    Healy MD; Malluche HH; Goldstein DA; Singer FR; Massry SG
    Arch Intern Med; 1980 Aug; 140(8):1030-3. PubMed ID: 6893118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1,25-dihydroxy-vitamin D3: a new treatment for hypoparathyroidism.
    Glatthaar C; Smith R; Espiner EA; Donald RA; Hinton D
    N Z Med J; 1980 Oct; 92(669):267-71. PubMed ID: 6934421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.
    Drezner MK; Lyles KW; Haussler MR; Harrelson JM
    J Clin Invest; 1980 Nov; 66(5):1020-32. PubMed ID: 6253520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolites and analogues of vitamin D. Which for what?
    Haussler MR; Cordy PE
    JAMA; 1982 Feb; 247(6):841-4. PubMed ID: 6895767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of 1,25-dihydroxy vitamin D3 and 24,25-dihydroxy vitamin D3 in renal osteodystrophy.
    Muirhead N; Adami S; Sandler LM; Fraser RA; Catto GR; Edward N; O'Riordan JL
    Q J Med; 1982; 51(204):427-44. PubMed ID: 6760236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.
    Voigts AL; Felsenfeld AJ; Llach F
    Arch Intern Med; 1983 Jun; 143(6):1205-11. PubMed ID: 6344827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
    Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE
    Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of 1,25-dihydroxyvitamin D3 in early renal failure.
    Goodman WG; Coburn JW
    Annu Rev Med; 1992; 43():227-37. PubMed ID: 1580587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 24,25 dihydroxycalciferol: assay in non-anephric patients on chronic haemodialysis and assessment of its possible pathophysiological role in renal osteodystrophy.
    Lambrey G; Nguyen TM; Fournier A; Sebert JL; Kassouf J; de Fremont JF; Marie P; Meunier P; Caillens C; Gueris J; Garabedian M; Balsan S
    Proc Eur Dial Transplant Assoc; 1980; 17():548-56. PubMed ID: 6972530
    [No Abstract]   [Full Text] [Related]  

  • 16. [Intestinal absorption of Ca47 in chronic renal insufficiency before and after treatment with 1,25 dihydroxycholecalciferol].
    Vattimo A
    Minerva Med; 1979 Dec; 70(54):3705-7. PubMed ID: 523001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,25-dihydroxycholesterol treatment of long-term haemodialysed patients with renal osteodystrophy.
    Váry L
    Int Urol Nephrol; 1980; 12(3):241-7. PubMed ID: 7251289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.
    Reichel H
    Nephron Clin Pract; 2010; 114(4):c268-76. PubMed ID: 20090369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic use of vitamin D, its derivatives and their analogs].
    Vagneur JP; Argemi B
    Diabete Metab; 1982 Mar; 8(1):65-7. PubMed ID: 6980150
    [No Abstract]   [Full Text] [Related]  

  • 20. Zinc metabolism in patients with chronic renal failure during treatment with 1.25-dihydroxycholecalciferol: a controlled therapeutic trial.
    Kiilerich S; Christiansen C; Christensen MS; Naestoft J
    Clin Nephrol; 1981 Jan; 15(1):23-7. PubMed ID: 7214749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.